At the news
? NEUTRALIMPACT 2/10 3 filed Nov 12, 2026 at 16:01 ET
Gregory Divis filed a Form 3 initial statement of beneficial ownership after becoming President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.) following a merger. The filing discloses options to purchase 1,454,398 shares at $10.37, vesting over three years. This is a routine Section 16 filing with no material price impact.
- Gregory Divis appointed President and CEO of InMed Pharmaceuticals Inc. (now Mentari Therapeutics Inc.)
- Filing is an initial statement of beneficial ownership (Form 3) under Section 16(a)
- Divis holds stock options to buy 1,454,398 shares at $10.36 per share
- Options vest 25% on July 20, 2027 and monthly thereafter through July 20, 2030
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access